Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Estrone sulfate
Drug ID BADD_D00835
Description Estrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis.
Indications and Usage Estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB04574
KEGG ID D00312
MeSH ID C017296
PubChem ID 3001028
TTD Drug ID Not Available
NDC Product Code Not Available
UNII QTL48N278K
Synonyms estrone sulfate | oestrone sulphate | estrone-3-sulfate | estrone sulfate, 16-(14)C-labeled | Evex | estrone sulfate, potassium salt | potassium estrone sulfate | estrone sulfate, sodium salt | sodium estrone sulfate | estrone sulfate, 14C-labeled | estrone sulfate, ammonium salt
Chemical Information
Molecular Formula C18H22O5S
CAS Registry Number 481-97-0
SMILES CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Tenderness08.01.08.005--Not Available
Tension19.06.02.005--Not Available
Thrombophlebitis24.01.02.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.001--
Uterine haemorrhage24.07.03.004; 21.07.01.005--
Uterine leiomyoma21.07.02.004; 16.04.02.001--Not Available
Vaginal discharge21.08.02.002--
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection21.14.02.002; 11.01.10.002--
Venous thrombosis24.01.01.008--Not Available
Vertigo04.04.01.003; 17.02.12.002--
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Weight increased13.15.01.006--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Endometrial thickening21.07.01.013--Not Available
Angiopathy24.03.02.007--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Porphyrin metabolism disorder14.14.01.006; 09.01.10.004; 03.08.01.006--Not Available
Polyp08.01.06.010; 16.02.02.005--Not Available
Hepatobiliary disease09.01.08.003--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages